Yep. Not for long though. Yanks will love this too. A more palatable product than Norvatis equivalent and this product alone is targetting £100M and we're priced at £20M. Expecting these chunky buys to continue to arriving all day... and beyond
WINS now a buyer. Just CFEP and we're off again. Going to be a cracking day here. Surely £30M today or by Monday. Placing price was 50p so a long way to go with the other five trials ongoing and very encouraging outcome from the latest!
They were hoping for an equivalent clinical palitability profile compared to the Novatis drug. However, have far exceeded in terms of delivery. At £22M Mcap seems a touch undervalued. Not for long though..
Interim data for key oncology drug candidate MTD201 establishes favourable clinical profile compared to reference product Novartis' Sandostatin® LAR® ("SLAR"),
i.e a safer more palitable product than Novartis equivalent in a study of 25. Ka ching
So when volume hits today this could easily see us open at 1p+ tomorrow first thing on this asset news and rightfully so. AAAP has now changed into a fascinating company with strong ambition. Looking forward to Leni's PR drive